PVR

Summary

PVR (PVR cell adhesion molecule, HGNC:9705) is a protein-coding gene on chromosome 19q13.31, encoding Poliovirus receptor (P15151). Mediates NK cell adhesion and triggers NK cell effector functions.

The protein encoded by this gene is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. The external domain mediates cell attachment to the extracellular matrix molecule vitronectin, while its intracellular domain interacts with the dynein light chain Tctex-1/DYNLT1. The gene is specific to the primate lineage, and serves as a cellular receptor for poliovirus in the first step of poliovirus replication. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 5817 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 93 total
• GTEx eGene: eQTL in 42 tissues, sQTL in 15 (q < 0.05)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.14 (unconstrained)
• MANE Select transcript: NM_006505
• Notable: 93 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9705
Approved symbol	PVR
Name	PVR cell adhesion molecule
Location	19q13.31
Locus type	gene with protein product
Status	Approved
Aliases	CD155, HVED, Necl-5, NECL5, Tage4
Ensembl gene	ENSG00000073008
Ensembl biotype	protein_coding
OMIM	173850
Entrez	5817

Gene structure

Transcript identifiers

Ensembl transcripts: 23 — 17 protein_coding, 4 nonsense_mediated_decay, 2 retained_intron

MANE Select: ENST00000425690

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 2, TSL 3: 1, TSL 5: 1

ENST00000425690, ENST00000187830, ENST00000344956, ENST00000403059, ENST00000406449, ENST00000587785, ENST00000706603, ENST00000706604, ENST00000706605, ENST00000706606, ENST00000706607, ENST00000706608, ENST00000937736, ENST00000971444, ENST00000971445, ENST00001032284, ENST00001032285, ENST00001032286, ENST00001032287, ENST00001112012, ENST00001125412, ENST00001125413, ENST00001139674

RefSeq mRNA: 4 — MANE Select: NM_006505 NM_001135768, NM_001135769, NM_001135770, NM_006505

CCDS: CCDS12640, CCDS46105, CCDS46106, CCDS46107

Canonical transcript exons

ENST00000425690 — 8 exons

Exon	Start	End
ENSE00000711638	44647223	44647570
ENSE00003500390	44657762	44657910
ENSE00003508640	44649809	44650105
ENSE00003603474	44653900	44654017
ENSE00003633879	44661292	44661323
ENSE00003671062	44658742	44658900
ENSE00003996294	44643910	44644175
ENSE00004795325	44661740	44666162

Expression profiles

Bgee: expression breadth ubiquitous, 213 present calls, max score 94.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.9136 / max 237.0141, expressed in 1740 samples.

Highest expression (Bgee): stromal cell of endometrium, islet of Langerhans, tendon of biceps brachii, heart left ventricle, apex of heart.

Genetic regulation across tissues (GTEx eQTL / sQTL)

PVR is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 42 tissues and its splicing (sQTL) in 15 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 57 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Muscle Skeletal	eqtl	1.3e-54	+0.56	19:44643329:A:G
Skin Not Sun Exposed Suprapubic	eqtl	1.9e-45	+0.57	19:44644040:G:T
Skin Sun Exposed Lower leg	eqtl	1.7e-39	+0.49	19:44644040:G:T
Cells Cultured fibroblasts	eqtl	3.9e-37	+0.25	19:44644040:G:T
Nerve Tibial	eqtl	2.9e-24	+0.26	19:44617725:A:G
Heart Atrial Appendage	eqtl	3.0e-21	+0.38	19:44643329:A:G
Adipose Subcutaneous	eqtl	2.1e-20	+0.26	19:44644040:G:T
Heart Left Ventricle	eqtl	3.5e-18	+0.27	19:44644040:G:T
Artery Tibial	eqtl	1.0e-14	-0.44	19:44647342:G:A
Esophagus Mucosa	eqtl	1.1e-14	+0.29	19:44644040:G:T
Cells Cultured fibroblasts	sqtl	9.7e-14	-1.74	19:44623160:C:T
Esophagus Muscularis	eqtl	2.4e-13	+0.17	19:44643329:A:G
Brain Caudate basal ganglia	eqtl	5.5e-13	+0.39	19:44644419:T:G
Brain Nucleus accumbens basal ganglia	eqtl	4.2e-12	+0.36	19:44643102:T:C
Brain Cerebellum	eqtl	1.5e-11	+0.42	19:44643329:A:G
Brain Frontal Cortex BA9	eqtl	2.1e-11	+0.33	19:44643329:A:G
Esophagus Gastroesophageal Junction	eqtl	5.1e-10	+0.20	19:44643329:A:G
Lung	sqtl	1.6e-09	-0.97	19:44645842:A:G
Brain Cerebellar Hemisphere	eqtl	3.5e-09	+0.32	19:44644419:T:G
Stomach	eqtl	2.1e-08	+0.25	19:44643329:A:G

FANTOM5 promoters

3 alternative TSS:

Promoter ID	TPM avg	Samples expressed
176264	26.2772	1734
176266	0.9289	372
176265	0.7075	401

Top tissues by expression

showing 100 of 271 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	94.30	gold quality
islet of Langerhans	UBERON:0000006	92.23	gold quality
tendon of biceps brachii	UBERON:0008188	91.18	gold quality
heart left ventricle	UBERON:0002084	90.60	gold quality
apex of heart	UBERON:0002098	90.60	gold quality
cardiac ventricle	UBERON:0002082	90.22	gold quality
right lobe of liver	UBERON:0001114	90.01	gold quality
upper lobe of left lung	UBERON:0008952	89.60	gold quality
adenohypophysis	UBERON:0002196	89.46	gold quality
upper lobe of lung	UBERON:0008948	89.09	gold quality
left adrenal gland	UBERON:0001234	89.06	gold quality
right atrium auricular region	UBERON:0006631	88.98	gold quality
sural nerve	UBERON:0015488	88.85	gold quality
right adrenal gland	UBERON:0001233	88.80	gold quality
right adrenal gland cortex	UBERON:0035827	88.74	gold quality
adrenal tissue	UBERON:0018303	88.64	gold quality
heart	UBERON:0000948	88.43	gold quality
adrenal gland	UBERON:0002369	88.39	gold quality
left adrenal gland cortex	UBERON:0035825	88.35	gold quality
pituitary gland	UBERON:0000007	88.22	gold quality
cardiac atrium	UBERON:0002081	87.83	gold quality
adrenal cortex	UBERON:0001235	87.74	gold quality
liver	UBERON:0002107	87.40	gold quality
ascending aorta	UBERON:0001496	87.38	gold quality
popliteal artery	UBERON:0002250	87.33	gold quality
thoracic aorta	UBERON:0001515	87.31	gold quality
tibial artery	UBERON:0007610	87.30	gold quality
cartilage tissue	UBERON:0002418	87.28	gold quality
aorta	UBERON:0000947	87.26	gold quality
right coronary artery	UBERON:0001625	87.23	gold quality
pancreas	UBERON:0001264	87.07	gold quality
left coronary artery	UBERON:0001626	87.06	gold quality
metanephros cortex	UBERON:0010533	87.06	gold quality
smooth muscle tissue	UBERON:0001135	86.48	gold quality
coronary artery	UBERON:0001621	86.40	gold quality
body of stomach	UBERON:0001161	86.14	gold quality
lower esophagus muscularis layer	UBERON:0035833	86.14	gold quality
lower esophagus	UBERON:0013473	86.10	gold quality
nerve	UBERON:0001021	86.09	gold quality
tibial nerve	UBERON:0001323	86.09	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.89	gold quality
gastrocnemius	UBERON:0001388	85.80	gold quality
body of pancreas	UBERON:0001150	85.70	gold quality
descending thoracic aorta	UBERON:0002345	85.60	gold quality
muscle of leg	UBERON:0001383	85.23	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	84.94	gold quality
omental fat pad	UBERON:0010414	84.79	gold quality
peritoneum	UBERON:0002358	84.76	gold quality
right lung	UBERON:0002167	84.65	gold quality
rectum	UBERON:0001052	84.59	gold quality
mucosa of transverse colon	UBERON:0004991	84.59	gold quality
left uterine tube	UBERON:0001303	84.48	gold quality
left ovary	UBERON:0002119	84.36	gold quality
left lobe of thyroid gland	UBERON:0001120	84.35	gold quality
stomach	UBERON:0000945	84.29	gold quality
right lobe of thyroid gland	UBERON:0001119	84.21	gold quality
transverse colon	UBERON:0001157	84.03	gold quality
cortical plate	UBERON:0005343	83.86	gold quality
adipose tissue of abdominal region	UBERON:0007808	83.79	gold quality
body of uterus	UBERON:0009853	83.58	gold quality
thyroid gland	UBERON:0002046	83.52	gold quality
right ovary	UBERON:0002118	83.27	gold quality
esophagus	UBERON:0001043	83.21	gold quality
adult mammalian kidney	UBERON:0000082	83.16	gold quality
right frontal lobe	UBERON:0002810	82.97	gold quality
muscle organ	UBERON:0001630	82.82	gold quality
skeletal muscle organ	UBERON:0014892	82.82	gold quality
lung	UBERON:0002048	82.73	gold quality
muscle layer of sigmoid colon	UBERON:0035805	82.69	gold quality
mucosa of stomach	UBERON:0001199	82.61	gold quality
colon	UBERON:0001155	82.60	gold quality
olfactory bulb	UBERON:0002264	82.53	gold quality
myometrium	UBERON:0001296	82.52	gold quality
ovary	UBERON:0000992	82.51	gold quality
sigmoid colon	UBERON:0001159	82.42	gold quality
large intestine	UBERON:0000059	82.33	gold quality
prostate gland	UBERON:0002367	82.27	gold quality
hypothalamus	UBERON:0001898	82.24	gold quality
minor salivary gland	UBERON:0001830	82.07	gold quality
mucosa of sigmoid colon	UBERON:0004993	81.91	gold quality
intestine	UBERON:0000160	81.88	gold quality
lower lobe of lung	UBERON:0008949	81.72	gold quality
cortex of kidney	UBERON:0001225	81.69	gold quality
prefrontal cortex	UBERON:0000451	81.63	gold quality
gall bladder	UBERON:0002110	81.50	gold quality
duodenum	UBERON:0002114	81.48	gold quality
ectocervix	UBERON:0012249	81.46	gold quality
cingulate cortex	UBERON:0003027	81.41	gold quality
right hemisphere of cerebellum	UBERON:0014890	81.23	gold quality
colonic mucosa	UBERON:0000317	81.19	gold quality
anterior cingulate cortex	UBERON:0009835	81.13	gold quality
right uterine tube	UBERON:0001302	81.11	gold quality
esophagus mucosa	UBERON:0002469	81.02	gold quality
saliva-secreting gland	UBERON:0001044	80.99	gold quality
placenta	UBERON:0001987	80.93	gold quality
mouth mucosa	UBERON:0003729	80.91	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	80.88	gold quality
Brodmann (1909) area 9	UBERON:0013540	80.86	gold quality
heart right ventricle	UBERON:0002080	80.74	silver quality
cerebellar hemisphere	UBERON:0002245	80.74	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.88
E-MTAB-5061	no	3.37

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 76 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Locus coeruleus	tissue	28.9
Choroid plexus	tissue	25.4
Postcentral gyrus	tissue	24.5
Hippocampus	tissue	20.0	not detected
Nucleus accumbens	tissue	17.9
Pituitary gland	tissue	15.1
Heart muscle	tissue	12.3	high
Liver	tissue	11.7	low
Hippocampal formation	tissue	10.9
Pancreas	tissue	10.2	medium
Skeletal muscle	tissue	9.9	not detected
Cerebral cortex	tissue	9.8	medium
Olfactory bulb	tissue	9.8
Insular cortex	tissue	9.8
Retrosplenial cortex	tissue	9.7
Retrosplenial and cingulate cortex	tissue	9.6
Amygdala	tissue	9.4
Occipital cortex	tissue	9.2
Duodenum	tissue	9.1	low
Temporal cortex	tissue	9.1
Placenta	tissue	9.0	high
Ventral forebrain	tissue	8.9
Somatosensory cortex	tissue	8.9
Cerebellum	tissue	8.7	low
Entorhinal cortex	tissue	8.7
Adrenal gland	tissue	8.6	medium
Basal ganglia	tissue	8.5	medium
Motor cortex	tissue	8.4
Small intestine	tissue	8.4	low
Prefrontal cortex	tissue	8.3
Lung	tissue	8.3	low
Corpus callosum	tissue	8.3
Smooth muscle	tissue	8.0	not detected
Septum	tissue	7.9
Hypothalamus	tissue	7.8
Putamen	tissue	7.5
Periaqueductal gray	tissue	7.4
Thalamus	tissue	7.3
Parathyroid gland	tissue	7.2	medium
Pons	tissue	7.1
Vagina	tissue	7.1	not detected
Substantia nigra	tissue	7.0
Stomach 1	tissue	6.9	medium
Colon	tissue	6.8	medium
Midbrain	tissue	6.7
Medulla oblongata	tissue	6.6
Superior colliculi	tissue	6.5
Rectum	tissue	6.2	medium
Spinal cord	tissue	5.9
Adipose tissue	tissue	5.6	not detected
Appendix	tissue	5.5	medium
Urinary bladder	tissue	5.2	not detected
Prostate	tissue	5.2	medium
Ovary	tissue	4.8	low
Gallbladder	tissue	4.7	medium
Salivary gland	tissue	4.5	not detected
Thyroid gland	tissue	4.4	medium
Bone marrow	tissue	4.3	not detected
Seminal vesicle	tissue	4.1	medium
Esophagus	tissue	4.1	low

Brain sub-regions (HPA Brain Atlas): detected in 190; highest nTPM — Arcuate nucleus (35.4), Ventromedial nucleus (32.8), Lateral hypothalamic area (29.1), Median raphe nucleus (28.7), Nucleus ambiguus (27.0).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, ATF2, ATM, DBP, E4F1, MYOD1, NFIL3, NRF1, SHH, SSRP1, TBP, TCF3, TFAP2A, TP53

miRNA regulators (miRDB)

Targeting PVR by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 120 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-383-3P	99.85	65.84	1359
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471

Functional genomics

gnomAD constraint: pLI 5.36e-11, LOEUF 1.14, missense Z 1.12 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000425690 — one region, missense o/e 0.87.

Literature-anchored findings (GeneRIF, showing 40)

• We propose that the cytoplasmic domain may target CD155-containing endocytic vesicles to the microtubular network (PMID:11751937)
• activation of expression of sonic hedgehog protein (PMID:11983699)
• Data show that both PVR and Nectin-2 represent specific ligands for the DNAM-1 triggering receptor. (PMID:12913096)
• CD155 may have an important role in cellular function (PMID:12943679)
• These data indicate that Tage4 represents the functional orthologue of CD155 in mouse. (PMID:14652024)
• that DNAM-1 regulates monocyte extravasation via its interaction with CD226 expressed at endothelial junctions on normal cells. (PMID:15136589)
• These results suggest that CD155alpha plays a role in the regulation of cell adhesion and cell motility. (PMID:15194502)
• cytoplasmic domain of PVR directly interacts with Tctex-1 and plays an important role in retrograde transport of poliovirus-containing vesicles along microtubules in vivo (PMID:15194795)
• Upregulation of the molecular target CD155 renders explant cultures of high-grade malignant gliomas highly susceptible to a prototype oncolytic poliovirus recombinant. (PMID:15279713)
• Analysis of the ligands for triggering NK receptors revealed the consistent expression of cd155 and cd112 in myeloid leukemias, and less frequent expression in lymphoblastic leukemias (PMID:15536144)
• Evasion of NK cell killing was mediated by human cytomegalovirus UL141 blocking surface expression of CD155 (PMID:15640804)
• Necl-5 has a critical role in integrin alphavbeta3 clustering and focal complex formation (PMID:17446174)
• Results describe the establishment of a poliovirus oral infection system in human poliovirus receptor-expressing transgenic mice that are deficient in alpha/beta interferon receptor. (PMID:17507470)
• no statistically significant association between this marker allele and non-syndromic clefting (PMID:17534374)
• CD155, at least in part, enhances the proliferation of ras-mutated cells (PMID:17893876)
• crystal structure of C155 D1D2 has been determined to 3.5-A resolution and fitted into approximately 8.5-A resolution cryoelectron microscopy reconstructions of the virus-receptor complexes for the 3 PV serotypes (PMID:19011098)
• CD96-driven adhesion to CD155 may be crucial in developmental processes (PMID:19056733)
• The Ala67Thr mutation in the poliovirus receptor is a possible risk factor for the development of vaccine-associated or paralytic poliomyelitis associated with wild-type virus. (PMID:19319949)
• evidence provided for the contribution of DNAM-1/CD155 interactions to the reduction of DNAM-1 expression, suggesting that chronic receptor-ligand interactions in the tumor environment may induce loss of DNAM-1 on tumor-associated NK cells. (PMID:19801517)
• TIGIT is expressed by all NK cells, it binds PVR and PVRL2 but not PVRL3, and it inhibits NK cytotoxicity (PMID:19815499)
• Necl-5 plays a role in mediating tumor cell invasion and that the overexpression of Necl-5 in cancer cells has clinical significance for prognostic evaluation of patients with primary pulmonary adenocarcinoma. (PMID:20331633)
• CD155 is an IFNgamma-inducible immune regulatory protein on the surface of human endothelial cells that attenuates the acquisition of effector functions in CD8 T cells. (PMID:21330602)
• Data show that a high expression of CD112 and CD155 (DNAM-1 ligands) on leukemic blasts. (PMID:21383766)
• The host TICAM-1 pathway, particularly in macrophages, serves as a source of type I interferon induction that protects poliovirus (PV) receptor-bearing transgenic mice from PV infection and paralytic death. (PMID:21998457)
• Expression of PVR in B-ALL cells is modulated by epigenetic mechanisms. (PMID:22169283)
• the PVR downmodulation by Nef and Vpu is a strategy evolved by HIV-1 to prevent NK cell-mediated lysis of infected cells. (PMID:22301152)
• This investigation has enhanced understanding of cell invasion and confirmed CD44 to play a more significant role in this biological process than CD155. (PMID:22363471)
• we demonstrated the expression of both CD155 mRNA and protein in bone and soft tissue sarcoma cell lines (PMID:22692919)
• The concordant computational and experimental data of the present study indicate that the extent of NECL-5 expression correlates with melanoma progression. (PMID:22929570)
• findings suggest Necl-5 expression in lung cancer cells is crucial for their invasiveness in the cancer-stromal interaction (PMID:23276719)
• PVR resides in the recently identified lateral border recycling compartment, similar to PECAM and CD99. (PMID:23333754)
• The CD226/CD155 interaction regulates the proinflammatory (Th1/Th17)/anti-inflammatory (Th2) balance in humans. (PMID:23980210)
• Vpr upregulates PVR during Hiv-1 infection by activating ATR kinase that triggers the DNA damage rsponse pathway and G2 arrest. (PMID:24045107)
• UL141 can inhibit cell-surface expression of both natural killer (NK) cell-activating ligand CD155 as well as TRAIL death receptors (TRAIL-R1 and TRAIL-R2). (PMID:24598754)
• TIGIT/PVR ligation signaling mediates suppression of IFN-gamma production via the NF-kappaB pathway. (PMID:24817116)
• In granulosa cells, there are significant changes in expression during follicular maturation. (PMID:24828608)
• Ala residues 10, 14 and 18 in the TM domain of Vpu are required for CD155 downregulation. (PMID:25113908)
• UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells. (PMID:25209846)
• Our findings suggest that loss of CD155 expression may play an important role in the immune escape of HCC cells and thus CD155 may serve as a prognostic marker as well as a potential therapeutic target for HCC. (PMID:25320021)
• The present study provides evidence that regulation of the PVR/CD155 DNAM-1 ligand expression by nitric oxide may represent an additional immune-mediated mechanism and supports the anti-myeloma activity of nitric oxide donors. (PMID:25609078)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
danio_rerio	zgc:113337	ENSDARG00000041998
danio_rerio	si:ch211-222f23.6	ENSDARG00000042880
danio_rerio	si:ch73-22o12.1	ENSDARG00000062831
danio_rerio	pvrl2l	ENSDARG00000063390
danio_rerio	sc:d189	ENSDARG00000079191
danio_rerio	si:ch211-214p13.3	ENSDARG00000087403
danio_rerio	si:ch211-141e20.2	ENSDARG00000093349
danio_rerio	sc:d189	ENSDARG00000102858
mus_musculus	Pvr	ENSMUSG00000040511
rattus_norvegicus	Pvr	ENSRNOG00000019202
drosophila_melanogaster	Fas3	FBGN0000636

Paralogs (14): CD200 (ENSG00000091972), CADM4 (ENSG00000105767), CRTAM (ENSG00000109943), NECTIN1 (ENSG00000110400), NECTIN2 (ENSG00000130202), NECTIN4 (ENSG00000143217), CD226 (ENSG00000150637), CADM3 (ENSG00000162706), SMAGP (ENSG00000170545), CADM2 (ENSG00000175161), NECTIN3 (ENSG00000177707), TIGIT (ENSG00000181847), CADM1 (ENSG00000182985), NCR3 (ENSG00000204475)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:107741) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 10 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased IgG level	1
decreased IgA level	1
increased circulating insulin level	1
decreased incidence of tumors by chemical induction	1
abnormal response to infection	1
abnormal incisor morphology	1
decreased IgG1 level	1
decreased IgG2a level	1
decreased IgG2b level	1
decreased physiological sensitivity to xenobiotic	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Sus scrofa	Q9GL76	92.8%	Diamond
Chlorocebus aethiops	P32506	89.9%	Diamond
Xenopus tropicalis	Q5FWR8	50.3%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
IGSF23	protein-coding	147710
CEACAM19	protein-coding	56971
MIR8085	ncRNA	102465879
CEACAM16	protein-coding	388551
BCL3	protein-coding	602
MIR4531	ncRNA	100616355
CEACAM16-AS1	ncRNA	107985305
CEACAM20	protein-coding	125931
ZNF180	protein-coding	7733

Protein

Protein identifiers

Poliovirus receptor — P15151 (reviewed: P15151)

Alternative names: Nectin-like protein 5

All UniProt accessions (9): A0A0A0MSA9, A0A0C4DG49, P15151, A0A9L9PX39, A0A9L9PXB8, A0A9L9PXN8, A0A9L9PY64, F8W7D4, K7EMC6

UniProt curated annotations — full annotation on UniProt →

Function. Mediates NK cell adhesion and triggers NK cell effector functions. Binds two different NK cell receptors: CD96 and CD226. These interactions accumulates at the cell-cell contact site, leading to the formation of a mature immunological synapse between NK cell and target cell. This may trigger adhesion and secretion of lytic granules and IFN-gamma and activate cytotoxicity of activated NK cells. May also promote NK cell-target cell modular exchange, and PVR transfer to the NK cell. This transfer is more important in some tumor cells expressing a lot of PVR, and may trigger fratricide NK cell activation, providing tumors with a mechanism of immunoevasion. Plays a role in mediating tumor cell invasion and migration. (Microbial infection) Acts as a receptor for poliovirus. May play a role in axonal transport of poliovirus, by targeting virion-PVR-containing endocytic vesicles to the microtubular network through interaction with DYNLT1. This interaction would drive the virus-containing vesicle to the axonal retrograde transport. (Microbial infection) Acts as a receptor for Pseudorabies virus. (Microbial infection) Is prevented to reach cell surface upon infection by Human cytomegalovirus /HHV-5, presumably to escape immune recognition of infected cell by NK cells.

Subunit / interactions. Can form trans-heterodimers with NECTIN3. The extracellular domain interacts with VTN, CD226 and CD96. The cytoplasmic domain interacts with DYNLT1. Binds with high affinity to TIGIT. (Microbial infection) Interacts with poliovirus capsid proteins. (Microbial infection) Interacts with human cytomegalovirus /HHV-5 UL141 protein. (Microbial infection) Interacts with pseudorabies virus gD protein.

Subcellular location. Cell membrane Cell membrane Secreted Secreted.

Post-translational modifications. N-glycosylated. N-glycan at Asn-120: Hex5HexNAc4. Phosphorylated by Src kinases on tyrosine residues in the ITIM motif upon ligation. Interaction with TIGIT is required for Phosphorylation.

Domain organisation. Contains 1 copy of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.

Induction. Transcriptionally regulated by SHH.

Miscellaneous. The V-type domain is necessary and sufficient for virus binding and uptake.

Similarity. Belongs to the nectin family.

Isoforms (4)

UniProt ID	Names	Canonical?
P15151-1	Alpha	yes
P15151-2	Beta
P15151-3	Gamma
P15151-4	Delta

RefSeq proteins (4): NP_001129240, NP_001129241, NP_001129242, NP_006496* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013162	CD80_C2-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR052659	Nectin/PVR	Family

Pfam: PF07686, PF08205

UniProt features (63 total): strand 27, glycosylation site 10, splice variant 5, disulfide bond 3, sequence variant 3, domain 3, topological domain 2, turn 2, signal peptide 1, chain 1, modified residue 1, transmembrane region 1, mutagenesis site 1, helix 1, region of interest 1, short sequence motif 1

Structure

Experimental structures (PDB)

13 structures by resolution:

PDB	Title	Method	Resolution (Å)
6ISC	complex structure of mCD226-ecto and hCD155-D1	X-RAY DIFFRACTION	2.2
6O3O	Structure of human DNAM-1 (CD226) bound to nectin-like protein-5 (necl-5)	X-RAY DIFFRACTION	2.8
6ARQ	Crystal structure of CD96 (D1) bound to CD155/necl-5 (D1-3)	X-RAY DIFFRACTION	2.88
3UDW	Crystal structure of the immunoreceptor TIGIT in complex with Poliovirus receptor …	X-RAY DIFFRACTION	2.9
3URO	Poliovirus receptor CD155 D1D2	X-RAY DIFFRACTION	3.5
4FQP	Crystal structure of human Nectin-like 5 full ectodomain (D1-D3)	X-RAY DIFFRACTION	3.6
3J8F	Cryo-EM reconstruction of poliovirus-receptor complex	ELECTRON MICROSCOPY	4
3EPC	CryoEM structure of poliovirus receptor bound to poliovirus type 1	ELECTRON MICROSCOPY	8
3EPD	CryoEM structure of poliovirus receptor bound to poliovirus type 3	ELECTRON MICROSCOPY	9
3EPF	CryoEM structure of poliovirus receptor bound to poliovirus type 2	ELECTRON MICROSCOPY	9
3J9F	Poliovirus complexed with soluble, deglycosylated poliovirus receptor (Pvr) at 4 degrees C	ELECTRON MICROSCOPY	9
1NN8	CryoEM structure of poliovirus receptor bound to poliovirus	ELECTRON MICROSCOPY	15
1DGI	Cryo-EM structure of human poliovirus(serotype 1)complexed with three domain CD155	ELECTRON MICROSCOPY	22

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P15151-F1	85.08	0.67

Human Protein Atlas

Protein class: CD markers, Predicted membrane proteins, Predicted secreted proteins, Predicted intracellular proteins, Plasma proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm; plasma membrane; vesicles

Antibody reliability (HPA): IH approved · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1)

Type	Positions
Phosphotyrosine	398

Disulfide bonds (3)

Type	Positions
Disulfide bond	49–123, 166–221, 266–312

Glycosylation sites (10)

Type	Positions
N-linked (glcnac…) asparagine	105, 188, 218, 237, 278, 307, 313, 360, 352
N-linked (glcnac…) (complex) asparagine	120

Mutagenesis-validated functional residues (1)

Position	Phenotype
369–372	partial loss of dynlt1 binding.

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 8; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

8 pathways:

ID	Pathway	Evidence
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	curated
R-HSA-420597	Nectin/Necl trans heterodimerization	curated
R-HSA-1280218	Adaptive Immune System	—
R-HSA-418990	Adherens junctions interactions	—
R-HSA-446728	Cell junction organization	—
R-HSA-1500931	Cell-Cell communication	—
R-HSA-421270	Cell-cell junction organization	—
R-HSA-168256	Immune System	—

MSigDB gene sets: 227 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, GOBP_POSITIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, MORF_MSH3, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_LEUKOCYTE_MEDIATED_IMMUNITY, MORF_BRCA1, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN, GOBP_NEGATIVE_REGULATION_OF_INNATE_IMMUNE_RESPONSE, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, GOCC_CELL_SURFACE, GOBP_LEUKOCYTE_MEDIATED_CYTOTOXICITY

GO Biological Process (11): positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target (GO:0002860), homophilic cell-cell adhesion (GO:0007156), heterophilic cell-cell adhesion (GO:0007157), natural killer cell mediated cytotoxicity (GO:0042267), susceptibility to natural killer cell mediated cytotoxicity (GO:0042271), negative regulation of natural killer cell mediated cytotoxicity (GO:0045953), positive regulation of natural killer cell mediated cytotoxicity (GO:0045954), susceptibility to T cell mediated cytotoxicity (GO:0060370), cell adhesion (GO:0007155), signal transduction (GO:0007165), symbiont entry into host cell (GO:0046718)

GO Molecular Function (6): virus receptor activity (GO:0001618), signaling receptor activity (GO:0038023), receptor ligand activity (GO:0048018), cell adhesion molecule binding (GO:0050839), cell adhesion mediator activity (GO:0098631), protein binding (GO:0005515)

GO Cellular Component (7): cytoplasm (GO:0005737), plasma membrane (GO:0005886), adherens junction (GO:0005912), focal adhesion (GO:0005925), cell surface (GO:0009986), membrane (GO:0016020), extracellular region (GO:0005576)

Reactome top-level categories

6 top-level categories:

Category	Pathways
Adaptive Immune System	1
Adherens junctions interactions	1
Immune System	1
Cell-cell junction organization	1
Cell junction organization	1
Cell-Cell communication	1

GO top-level categories

37 GO namespaces:

Category	Terms
cellular anatomical structure	4
positive regulation of natural killer cell mediated cytotoxicity	2
cell-cell adhesion	2
natural killer cell mediated cytotoxicity	2
regulation of natural killer cell mediated cytotoxicity	2
cellular process	2
natural killer cell mediated cytotoxicity directed against tumor cell target	1
positive regulation of natural killer cell mediated immune response to tumor cell	1
regulation of natural killer cell mediated cytotoxicity directed against tumor cell target	1
leukocyte mediated cytotoxicity	1
natural killer cell mediated immunity	1
negative regulation of leukocyte mediated cytotoxicity	1
negative regulation of natural killer cell mediated immunity	1
positive regulation of leukocyte mediated cytotoxicity	1
positive regulation of natural killer cell mediated immunity	1
positive regulation of T cell mediated cytotoxicity	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
viral life cycle	1
symbiont entry into host	1
symbiont entry into host cell	1
exogenous protein binding	1
molecular transducer activity	1
signaling receptor binding	1
signal transduction	1
signaling receptor activator activity	1
protein binding	1
cell adhesion	1
cell adhesion molecule binding	1
binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
cell-cell junction	1
cell-substrate junction	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 12 of 25 annotations. The rest are phylogenetic / computational / electronic (IEA).

12 experimentally-supported GO terms:

GO term	NS	Evidence
natural killer cell mediated cytotoxicity	BP	direct assay
negative regulation of natural killer cell mediated cytotoxicity	BP	direct assay
positive regulation of natural killer cell mediated cytotoxicity	BP	mutant phenotype
positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target	BP	mutant phenotype
susceptibility to T cell mediated cytotoxicity	BP	direct assay
susceptibility to natural killer cell mediated cytotoxicity	BP	mutant phenotype
cell surface	CC	direct assay
focal adhesion	CC	high-throughput assay
membrane	CC	direct assay
plasma membrane	CC	direct assay
cell adhesion molecule binding	MF	physical interaction
receptor ligand activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,456 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PVR	CD226	Q15762	958
PVR	CD96	P40200	941
PVR	NCR3	O14931	859
PVR	TIGIT	Q495A1	857
PVR	NCR1	O76036	817
PVR	AFDN	P55196	720
PVR	KLRK1	P26718	716
PVR	ULBP1	Q9BZM6	678
PVR	CD274	Q9NZQ7	671
PVR	PVRIG	Q6DKI7	663
PVR	ULBP2	Q9BZM5	663
PVR	HAVCR2	Q8TDQ0	655
PVR	LAG3	P18627	650
PVR	CD8A	P01732	648
PVR	MICB	P79525	646

IntAct

Human interaction partners of PVR in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

showing 30 of 71 partners by confidence:

Partner	Interaction type	MIscore	Records
CD226	direct interaction	0.860	6
TIGIT	direct interaction	0.790	5
SLC30A2	physical association	0.780	11
KIR2DL5A	physical association	0.750	7
KRTAP10-8	physical association	0.720	6
CD96	association	0.700	3
NOTCH2NLA	physical association	0.670	4
SFTPC	physical association	0.670	3
NECTIN3	physical association	0.610	3
ADIPOQ	physical association	0.560	3
ANKRD46	physical association	0.560	3
AQP10	physical association	0.560	3
BRICD5	physical association	0.560	3
CD47	physical association	0.560	3
CLDN19	physical association	0.560	3
CTXN3	physical association	0.560	3
CYB561A3	physical association	0.560	3
CYSRT1	physical association	0.560	3
EBP	physical association	0.560	3
EDDM3B	physical association	0.560	3
GPRC5D	physical association	0.560	3
HHATL	physical association	0.560	3
HOXA1	physical association	0.560	3
INSIG2	physical association	0.560	3
KRTAP1-1	physical association	0.560	3
KRTAP1-3	physical association	0.560	3
KRTAP10-7	physical association	0.560	3
KRTAP10-9	physical association	0.560	3
KRTAP3-1	physical association	0.560	3
KRTAP3-3	physical association	0.560	3

BioGRID (214 interactions; top human partners by supporting records): RYK (Affinity Capture-MS; 3 records), ALG11 (Affinity Capture-MS; 2 records), ALG5 (Affinity Capture-MS; 2 records), ARV1 (Affinity Capture-MS; 2 records), ATR (Affinity Capture-MS; 2 records), C4A (Affinity Capture-MS; 2 records), CD96 (Affinity Capture-MS; 2 records), CDON (Affinity Capture-MS; 2 records), CISD2 (Affinity Capture-MS; 2 records), DYNLT1 (Two-hybrid; 2 records), EFNB1 (Affinity Capture-MS; 2 records), FAM134A (Affinity Capture-MS; 2 records), FAM20B (Affinity Capture-MS; 2 records), GNPAT (Affinity Capture-MS; 2 records), GPD2 (Affinity Capture-MS; 2 records)

SIGNOR signaling

4 signaling interactions:

A	Effect	B	Mechanism
ATM	“up-regulates quantity by expression”	PVR	“transcriptional regulation”
PVR	“up-regulates activity”	CD226	binding
PVR	“up-regulates activity”	TIGIT	binding
MARCHF9	“down-regulates quantity by destabilization”	PVR	ubiquitination

Ligand–receptor pairs (CellPhoneDB) (5)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

5 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
TIGIT	ligand	Signaling by Poliovirus receptor
KIR2DL5A	ligand
NECTIN3	receptor	Signaling by Nectin
CD226	ligand	Signaling by Poliovirus receptor
CD96	ligand	Signaling by Poliovirus receptor

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 71 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	9	12.5×	5e-06

Disease & clinical

Genetic variants

Variant evidence for PVR: 93 ClinVar records (0 pathogenic / likely pathogenic); 18 GWAS associations.

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	9
Benign	6

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 39 predictions of 555):

Position(s)	Effect	Δscore	Sites
19:44644177	donor_loss	1.0000
19:44647543	donor_gain	1.0000
19:44647571–44647572	donor_loss	1.0000	4
19:44657911–44657912	donor_loss	1.0000	5
19:44644176–44644177	donor_loss	0.9900	4
19:44647221–44647222	acceptor_loss	0.9900	6
19:44647571	donor_loss	0.9900
19:44653898–44653899	acceptor_loss	0.9900	6
19:44654018–44654019	donor_loss	0.9900	5
19:44657760–44657761	acceptor_loss	0.9900	6

AlphaMissense

409 missense substitutions predicted likely pathogenic (of 2,679 scored), across 131 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D117	8	0.941	0.984
C312	7	0.984	0.996
C266	7	0.981	0.993
C123	7	0.975	0.991
C166	7	0.975	0.992
C221	7	0.975	0.991
C49	7	0.969	0.988
W279	7	0.968	0.998
F94	7	0.960	0.995
W179	7	0.954	0.998
W66	7	0.934	0.996
F128	7	0.904	0.985
N316	7	0.878	0.986
F78	7	0.866	0.952
S270	7	0.850	0.987
H225	7	0.847	0.940
W255	7	0.843	0.981
P145	6	0.897	0.979
S204	6	0.859	0.963
P272	6	0.857	0.936

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Lung Adenocarcinoma (TCGA)	unfavorable	5.78e-06
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	unfavorable	0.000101

Disease associations

OMIM: gene MIM:173850 | disease phenotypes:

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (1 panels, 0 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

1 panels:

Panel	Rating
COVID-19 research	amber

GWAS associations

18 associations:

Study	Trait	p-value
GCST002422_1	Alzheimer’s disease	9e-116
GCST007827_5	Alzheimer’s disease or HDL levels (pleiotropy)	7e-74
GCST007827_6	Alzheimer’s disease or HDL levels (pleiotropy)	7e-54
GCST007827_8	Alzheimer’s disease or HDL levels (pleiotropy)	3e-36
GCST90002395_325	Mean platelet volume	5e-18
GCST004599_94	Mean platelet volume	1e-17
GCST007320_6	Alzheimer’s disease or family history of Alzheimer’s disease	4e-17
GCST90002401_248	Platelet distribution width	6e-15
GCST90002395_324	Mean platelet volume	9e-15
GCST007827_17	Alzheimer’s disease or HDL levels (pleiotropy)	3e-12
GCST005952_8	Body mass index (age>50)	9e-12
GCST007827_19	Alzheimer’s disease or HDL levels (pleiotropy)	3e-11
GCST005950_15	Body mass index x sex x age interaction (4df test)	2e-10
GCST004599_95	Mean platelet volume	1e-9
GCST005954_4	Body mass index x age interaction	2e-7
GCST001198_72	Multiple sclerosis	1e-6
GCST005951_66	Body mass index	1e-6
GCST007124_7	Multiple sclerosis and HDL levels (pleiotropy)	4e-6

EFO canonical traits (from GWAS)

6 canonical traits:

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0009268	family history of Alzheimer’s disease
EFO:0007984	platelet component distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Immunoglobulin like domain containing proteins

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects expression, increases expression	4
bisphenol A	affects expression, increases expression	3
Cisplatin	affects cotreatment, decreases expression, increases expression	2
Lipopolysaccharides	affects response to substance, increases expression, affects expression	2
Nickel	increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Valproic Acid	increases expression, increases methylation	2
dicrotophos	increases expression	1
lasiocarpine	decreases expression	1
deoxynivalenol	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression, increases expression	1
perfluorooctanoic acid	increases expression	1
manganese chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
torcetrapib	increases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	decreases expression	1
Folic Acid	decreases expression	1
Gold	affects binding, decreases expression	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Manganese	decreases expression	1

Cellosaurus cell lines

12 cell lines: 6 transformed cell line, 4 cancer cell line, 2 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2PN	Abcam A-549 PVR KO	Cancer cell line	Male
CVCL_B3FF	Abcam HEK293T PVR KO	Transformed cell line	Female
CVCL_D9Q6	Ubigene HEK293 PVR KO	Transformed cell line	Female
CVCL_E1K7	HyCyte HEK293 KO-hPVR	Transformed cell line	Female
CVCL_E5IP	CHO-K1/CD155	Spontaneously immortalized cell line	Female
CVCL_E6RJ	Genomeditech CHO-K1 H_PVR(CD155)	Spontaneously immortalized cell line	Female
CVCL_E6WN	Genomeditech Raji H_PVR(CD155)	Cancer cell line	Male
CVCL_TH76	HAP1 PVR (-) 1	Cancer cell line	Male
CVCL_TH77	HAP1 PVR (-) 2	Cancer cell line	Male
CVCL_U966	TgSVA	Transformed cell line	Sex unspecified

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.